These data highlight the importance of the chemotherapy backbone to the immune response in HER2+ breast cancer, and the need for additional work in this area in order to optimise the anti-tumour immune response, particularly in conjunction with therapeutic antibodies. This evidence concerns the gene ERBB2 and breast carcinoma.